Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Endo International (ENDP) Share Price

News stories about Endo International (NASDAQ:ENDP) (TSE:ENL) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endo International earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.4639985614005 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

Shares of Endo International (NASDAQ:ENDP) opened at $7.95 on Friday. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86. The company has a market capitalization of $1,775.35, a PE ratio of -0.35, a price-to-earnings-growth ratio of 2.73 and a beta of 0.59. Endo International has a 1 year low of $5.77 and a 1 year high of $14.45.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. The firm had revenue of $786.90 million during the quarter, compared to analyst estimates of $794.93 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The business’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.01 earnings per share. sell-side analysts expect that Endo International will post 3.67 EPS for the current year.

A number of research firms recently commented on ENDP. BidaskClub cut Endo International from a “hold” rating to a “sell” rating in a research report on Thursday. Cantor Fitzgerald set a $7.00 price objective on Endo International and gave the company a “hold” rating in a research report on Thursday. Mizuho reiterated a “buy” rating and set a $12.00 price objective (down previously from $14.00) on shares of Endo International in a research report on Wednesday, January 3rd. Leerink Swann initiated coverage on Endo International in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $12.00 price target for the company. Finally, ValuEngine cut Endo International from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $11.27.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Endo International (ENDP) Share Price” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Insider Buying and Selling by Quarter for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with's FREE daily email newsletter.

Leave a Reply